Reimbursement scheme Forxiga®

General information

TerugBetaalRegeling Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF) has been stopped.

From July 1st 2023 onwards, Forxiga® (dapagliflozin) 10 mg for symptomatic chronic heart failure is fully reimbursement by the health insurer. Therefore the TerugBetaalRegeling (TBR) Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF & HFpEF) has been stopped. The manufacturer of this medicine has reimbursed the costs of the personal contribution to the patient from February 13th until June 30th 2023.

For a complete reimbursement overview of Forxiga® (dapagliflozin) 10 mg, click here

For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.

Dose	Forxiga® 10mg
Type	Tablets
Active ingredient	DAPAGLIFLOZINE

Reimbursement

Conditions

Declaration with an issue date between the above dates can still be submitted until November 1st 2023.

Who can submit a claim

Patients or their caregiver can claim the Personal Contribution for Forxiga® (dapagliflozine) 10mg online or by mail.
Pharmacists can only claim this medicine online on behalf of the patient.